Vir Biotechnology and GSK Announce Global Expansion to Phase 3 of COMET-ICE Study Evaluating VIR-7831 for the Treatment of COVID-19

06 October 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial - Intent to Care Early) study evaluating...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials